77 related articles for article (PubMed ID: 16259048)
21. The death of cost-minimization analysis?
Briggs AH; O'Brien BJ
Health Econ; 2001 Mar; 10(2):179-84. PubMed ID: 11252048
[TBL] [Abstract][Full Text] [Related]
22. Assessing the costs, benefits, cost-effectiveness, and cost-benefit of psychological assessment: we should, we can, and here's how.
Yates BT; Taub J
Psychol Assess; 2003 Dec; 15(4):478-95. PubMed ID: 14692844
[TBL] [Abstract][Full Text] [Related]
23. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
Elbasha EH
Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
[TBL] [Abstract][Full Text] [Related]
24. Addressing risk preferences in cost-effectiveness analyses.
Zivin JG; Bridges JF
Appl Health Econ Health Policy; 2002; 1(3):135-9. PubMed ID: 14619264
[TBL] [Abstract][Full Text] [Related]
25. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data.
Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG
Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness acceptability curves--caveats quantified.
Jakubczyk M; Kamiński B
Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
[TBL] [Abstract][Full Text] [Related]
27. [Bayesian approach for the cost-effectiveness evaluation of healthcare technologies].
Berchialla P; Gregori D; Brunello F; Veltri A; Petrinco M; Pagano E
Epidemiol Prev; 2009; 33(3):123-8. PubMed ID: 19776461
[TBL] [Abstract][Full Text] [Related]
28. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.
Briggs AH
Int J Technol Assess Health Care; 2001; 17(1):69-82. PubMed ID: 11329846
[TBL] [Abstract][Full Text] [Related]
29. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
Briggs AH; O'Brien BJ; Blackhouse G
Annu Rev Public Health; 2002; 23():377-401. PubMed ID: 11910068
[TBL] [Abstract][Full Text] [Related]
30. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
Zethraeus N; Johannesson M; Jönsson B; Löthgren M; Tambour M
Pharmacoeconomics; 2003; 21(1):39-48. PubMed ID: 12484802
[TBL] [Abstract][Full Text] [Related]
31. A framework for cost-effectiveness analysis from clinical trial data.
O'Hagan A; Stevens JW
Health Econ; 2001 Jun; 10(4):303-15. PubMed ID: 11400253
[TBL] [Abstract][Full Text] [Related]
32. A Bayesian approach to stochastic cost-effectiveness analysis.
Briggs AH
Health Econ; 1999 May; 8(3):257-61. PubMed ID: 10348420
[TBL] [Abstract][Full Text] [Related]
33. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.
Nixon RM; Thompson SG
Health Econ; 2005 Dec; 14(12):1217-29. PubMed ID: 15945043
[TBL] [Abstract][Full Text] [Related]
34. Can we justify the cost of echocardiography? Lessons from outcomes research.
Marwick TH
Eur J Echocardiogr; 2005 Jun; 6(3):155-63. PubMed ID: 15894234
[TBL] [Abstract][Full Text] [Related]
35. Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):43-6. PubMed ID: 24910291
[TBL] [Abstract][Full Text] [Related]
36. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.
O'Hagan A; Stevens JW; Montmartin J
Pharmacoeconomics; 2000 Apr; 17(4):339-49. PubMed ID: 10947489
[TBL] [Abstract][Full Text] [Related]
37. Treatment effectiveness score as an outcome measure in clinical trials.
Ling W; Shoptaw S; Wesson D; Rawson RA; Compton M; Klett CJ
NIDA Res Monogr; 1997; 175():208-20. PubMed ID: 9467800
[No Abstract] [Full Text] [Related]
38. Monitoring gas exchange: clinical effectiveness and cost considerations.
Durbin CG
Respir Care; 1994 Feb; 39(2):123-37. PubMed ID: 10145962
[No Abstract] [Full Text] [Related]
39. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
Fenwick E; O'Brien BJ; Briggs A
Health Econ; 2004 May; 13(5):405-15. PubMed ID: 15127421
[TBL] [Abstract][Full Text] [Related]
40. Bayesian sample size determination for cost-effectiveness studies with censored data.
Beavers DP; Stamey JD
PLoS One; 2018; 13(1):e0190422. PubMed ID: 29304143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
